AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12359169 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical projection pursuit method
Number of subjects: 32
Study 12359169 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended projection pursuit method
Number of subjects: 32
Study 12359169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of selected ERP time segments across different electrodes
Number of subjects: 32
Study 10214656 — intervention group
Group type: EXPERIMENTAL
Intervention: Music condition
Number of subjects: 15
Study 10214656 — intervention group
Group type: COMPARATOR
Intervention: Nonmusic condition
Number of subjects: 15
Study 7818154 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt‐PA)
Number of subjects: 312
Study 2361594 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-green argon laser
Number of subjects: 16
Study 2361594 — intervention group
Group type: EXPERIMENTAL
Intervention: Red krypton laser
Number of subjects: 16
Study 2361594 — intervention group
Group type: COMPARATOR
Intervention: Both lasers
Number of subjects: 16
Study 469699 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of control over electric shock (three conditions)
Number of subjects: 72
Study 469699 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of state anxiety
Number of subjects: 72
Study 29809075 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS) 50 or 75 mg
Number of subjects: 0
Study 29809075 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release MAS (MAS IR) 25 mg
Number of subjects: 0
Study 29809075 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS)
Number of subjects: 0
Study 27168455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product (100 g, twice daily for 3 months)
Number of subjects: 599
Study 27168455 — intervention group
Group type: COMPARATOR
Intervention: Control product (100 g, twice daily for 3 months)
Number of subjects: 599
Study 25913823 — intervention group
Group type: EXPERIMENTAL
Intervention: Energetic program (self-management group program)
Number of subjects: 0
Study 25913823 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 23070058 — intervention group
Group type: EXPERIMENTAL
Intervention: PAF-R antagonist CV3988
Number of subjects: 48
Study 23070058 — intervention group
Group type: COMPARATOR
Intervention: Poor glycaemic control
Number of subjects: 48
Study 23070058 — intervention group
Group type: COMPARATOR
Intervention: Good glycaemic control
Number of subjects: 48
Study 20884953 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered online cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 20884953 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18579828 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Clinical (QC) with meta-search filters
Number of subjects: 75
Study 18579828 — intervention group
Group type: COMPARATOR
Intervention: Library Model (LM) without meta-search filters
Number of subjects: 75
Study 18579828 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Clinical (QC)
Number of subjects: 75
Study 18579828 — intervention group
Group type: COMPARATOR
Intervention: Library Model (LM)
Number of subjects: 75
Study 16856976 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 37
Study 16856976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 16856976 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 14700438 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cleaning with bait traps containing insecticide
Number of subjects: 49
Study 14700438 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cleaning with bait traps without insecticide
Number of subjects: 49
Study 14700438 — intervention group
Group type: COMPARATOR
Intervention: No cleaning or bait traps
Number of subjects: 49
Study 14700438 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cleaning (both with and without insecticide)
Number of subjects: 49
Study 10992833 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 1.5 mg kg‐1
Number of subjects: 60
Study 10992833 — intervention group
Group type: COMPARATOR
Intervention: rocuronium 0.6 mg kg‐1
Number of subjects: 60
Study 8877664 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap combined with a free connective tissue graft
Number of subjects: 67
Study 8877664 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap alone
Number of subjects: 67
Study 8877664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and control groups
Number of subjects: 67
Study 1842141 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (60 mg/day for 3 weeks)
Number of subjects: 29
Study 1842141 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (270 mg/day for 3 weeks)
Number of subjects: 29
Study 1842141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6137293 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy (coronary artery bypass surgery)
Number of subjects: 780
Study 6137293 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 780
Study 29926158 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HU) and placebo, 18 patients
Number of subjects: 54
Study 29926158 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol/piperine and placebo, 16 patients
Number of subjects: 54
Study 29926158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) and resveratrol/piperine, 20 patients
Number of subjects: 54
Study 27410162 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise program (10 weeks)
Number of subjects: 28
Study 27410162 — intervention group
Group type: COMPARATOR
Intervention: Health status monitoring (Control group)
Number of subjects: 28
Study 24839887 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational problem-solving group intervention (n = 27)
Number of subjects: 55
Study 24839887 — intervention group
Group type: COMPARATOR
Intervention: Nonstructured group intervention (n = 28)
Number of subjects: 55
Study 23063316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (2 mg/kg per day for 1 week, followed by oral drug until day 98)
Number of subjects: 115
Study 23063316 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (5 mg/kg on days 0, 14, and 42)
Number of subjects: 115
Study 23063316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 115
Study 23063316 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 115
Study 20367484 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (HG)
Number of subjects: 40
Study 20367484 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NG)
Number of subjects: 40
Study 19137912 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product of tinidazole
Number of subjects: 24
Study 19137912 — intervention group
Group type: COMPARATOR
Intervention: Reference product of tinidazole
Number of subjects: 24
Study 15467292 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (ampicillin and gentamicin for 3 days)
Number of subjects: 148
Study 15467292 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 148
Study 12073051 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 48
Study 12073051 — intervention group
Group type: COMPARATOR
Intervention: Bone scan
Number of subjects: 48
Study 12166532 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone (1,200‐1,300 kcal/day)
Number of subjects: 91
Study 12166532 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (five 45 minute sessions per week at 78.4±0.5% maximum heart rate)
Number of subjects: 91
Study 12166532 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet
Number of subjects: 91
Study 12166532 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 10223751 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted resection
Number of subjects: 201
Study 10223751 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 201
Study 7884123 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home primary care by an interdisciplinary team (physician, physical therapist, 24-hour nursing services, geriatric consultation)
Number of subjects: 249
Study 7884123 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard district nurse-administered services at home)
Number of subjects: 249
Study 2144152 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrantectomy, axillary dissection and radiotherapy on the ipsilateral breast
Number of subjects: 701
Study 2144152 — intervention group
Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 701
Study 2144152 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrantectomy
Number of subjects: 701
Study 512076 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracene plus UVA light
Number of subjects: 5
Study 31773208 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 valerate (2, 4, 6, or 12 mg)
Number of subjects: 125
Study 31773208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 30760332 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) with silver-impregnated dressings via RENASYS TOUCH™ vacuum pump
Number of subjects: 104
Study 30760332 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy consisting of Acticoat™ and Mepitel™
Number of subjects: 104
Study 28668276 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group intervention (11-week, weekly 1-hour sessions, maintenance of 10,000 steps/day)
Number of subjects: 41
Study 28668276 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group intervention
Number of subjects: 41
Study 28668276 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study 25803441 — intervention group
Group type: EXPERIMENTAL
Intervention: CPIA (continuous propofol infusion by anesthesiologist)
Number of subjects: 154
Study 25803441 — intervention group
Group type: COMPARATOR
Intervention: IMIE (intermittent midazolam/propofol injection by endoscopist)
Number of subjects: 154
Study 23969308 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine therapy with dose delays or dose reductions (DD/DR) after achieving best objective response.
Number of subjects: 122
Study 23969308 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine therapy with dose delays or dose reductions (DD/DR) before achieving best objective response.
Number of subjects: 122
Study 23969308 — intervention group
Group type: COMPARATOR
Intervention: No dose delays or dose reductions (no DD/DR).
Number of subjects: 122
Study 21362272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% hyperbaric ropivacaine
Number of subjects: 40
Study 21362272 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine
Number of subjects: 40
Study 21362272 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine compared to bupivacaine
Number of subjects: 40
Study 19089438 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone treatment (intramuscular injection of 12 mg every 24 hours)
Number of subjects: 60
Study 19089438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19089438 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone treatment
Number of subjects: 60
Study 17898365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 66
Study 17898365 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gelatin solution
Number of subjects: 66
Study 17898365 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate solution
Number of subjects: 66
Study 17898365 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids (hydroxyethyl starch and modified gelatin)
Number of subjects: 66
Study 17898365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (Hemocomplettan) administered at 30 mg/kg
Number of subjects: 66
Study 15476757 — intervention group
Group type: EXPERIMENTAL
Intervention: Woolen hats
Number of subjects: 126
Study 15476757 — intervention group
Group type: COMPARATOR
Intervention: Cotton diapers
Number of subjects: 126
Study 11508513 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 329
Study 11508513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 11508513 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS) and Placebo
Number of subjects: 329
Study 10166597 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach visits by trained nurse facilitators
Number of subjects: 95
Study 10166597 — intervention group
Group type: COMPARATOR
Intervention: Feedback method (provision of a feedback report with advice)
Number of subjects: 95
Study 7911010 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (0.14 mg/nostril twice daily)
Number of subjects: 219
Study 7911010 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 219
Study 7911010 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 219
Study 7911010 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 219
Study 2906953 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (acute and chronic treatment)
Number of subjects: 51
Study 2906953 — intervention group
Group type: COMPARATOR
Intervention: i.v. Metoprolol (acute treatment)
Number of subjects: 51
Study 2906953 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, Metoprolol, Pindolol, Propranolol (chronic treatment)
Number of subjects: 51
Study 2906953 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (acute and chronic)
Number of subjects: 51
Study 2906953 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (5-month treatment)
Number of subjects: 51
Study 29893790 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with endocrine therapy (ET)
Number of subjects: 115
Study 29893790 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib monotherapy
Number of subjects: 115
Study 26607829 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-G needle
Number of subjects: 144
Study 26607829 — intervention group
Group type: COMPARATOR
Intervention: 22-G needle
Number of subjects: 144
Study 26607829 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover (both groups)
Number of subjects: 144
Study 26607829 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-G needle after crossover
Number of subjects: 144
Study 26607829 — intervention group
Group type: COMPARATOR
Intervention: 22-G needle after crossover
Number of subjects: 144
Study 24899137 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1,000 mg twice daily
Number of subjects: 144
Study 24899137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 21978861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow oxygen therapy
Number of subjects: 340
Study 21978861 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy (2-4 L/min via simple facemask or nasal cannulae)
Number of subjects: 340
Study 20019672 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 2171
Study 20019672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2171
Study 20019672 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 2171
Study 18614956 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (supervised, twice weekly for 8 weeks, consisting of three sets each of leg press, leg curl, and calf press)
Number of subjects: 16
Study 18614956 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 16
Study 15845688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 microg/kg IV)
Number of subjects: 18
Study 15845688 — intervention group
Group type: COMPARATOR
Intervention: Control (no fentanyl)
Number of subjects: 18
Study 15361060 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-publishing RCTs in RCT Bank
Number of subjects: 7
Study 10950043 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol rectal suppositories (200 microg tablets, 1 h before each radiation session)
Number of subjects: 16
Study 10950043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cocoa butter, 1 h before each radiation session)
Number of subjects: 16
Study 8839313 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Treatment Program
Number of subjects: 54
Study 1385372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight dextran + naftidrofuryl
Number of subjects: 80
Study 1385372 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight dextran
Number of subjects: 80
Study 3918431 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of beta-galactosidase from Kluyveromyces lactis
Number of subjects: 0
Study 3918431 — intervention group
Group type: COMPARATOR
Intervention: Sucrase
Number of subjects: 0
Study 3918431 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-galactosidase from Aspergillus niger
Number of subjects: 0
Study 3806896 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (one short course)
Number of subjects: 124
Study 3806896 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 124
Study 3806896 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy
Number of subjects: 124
Study 31137030 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trials
Number of subjects: 0
Study 31137030 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative 'efficient' trial designs
Number of subjects: 0
Study 31137030 — intervention group
Group type: EXPERIMENTAL
Intervention: Large multicentre trials
Number of subjects: 0
Study 31606589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine 2.16 mg/day
Number of subjects: 681
Study 31606589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine 2.88 mg/day
Number of subjects: 681
Study 31606589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 681
Study 31606589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (all doses)
Number of subjects: 681
Study 31606589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (at higher concentrations)
Number of subjects: 681
Study 28442303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ropinirole CR (18-24 mg/day)
Number of subjects: 81
Study 28442303 — intervention group
Group type: COMPARATOR
Intervention: Maintenance ropinirole CR (16 mg/day)
Number of subjects: 81
Study 28442303 — intervention group
Group type: COMPARATOR
Intervention: Comparison between high-dose and maintenance groups
Number of subjects: 81
Study 26657066 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation to mothers during the perinatal period
Number of subjects: 54
Study 26657066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23622849 — intervention group
Group type: COMPARATOR
Intervention: Medication switch alone (to another SSRI or to venlafaxine)
Number of subjects: 334
Study 23622849 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication switch plus cognitive behavioral therapy (CBT)
Number of subjects: 334
Study 23622849 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission (achieved by either treatment)
Number of subjects: 334
Study 23622849 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 334
Study 23622849 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 334
Study 21472495 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendar with health messages (n=2695)
Number of subjects: 5633
Study 21472495 — intervention group
Group type: COMPARATOR
Intervention: Calendar without health messages (n=2668)
Number of subjects: 5633
Study 18077078 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated CO(2) exposures in a standardized rebreathing test
Number of subjects: 31
Study 16603606 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin guidance for antibiotic therapy
Number of subjects: 302
Study 16603606 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual practice)
Number of subjects: 302
Study 12149660 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine therapy
Number of subjects: 23
Study 9539593 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 2061
Study 9539593 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 0.625 mg
Number of subjects: 2061
Study 9539593 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg
Number of subjects: 2061
Study 9539593 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2061
Study 7614176 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of twice daily Peridex rinse (0.12% chlorhexidine gluconate) after surgery
Number of subjects: 371
Study 7614176 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 1)
Number of subjects: 371
Study 7614176 — intervention group
Group type: COMPARATOR
Intervention: One rinse presurgery (group 3)
Number of subjects: 371
Study 2109558 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral tobramycin and ticarcillin (n = 7)
Number of subjects: 12
Study 2109558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 12
Study 662565 — intervention group
Group type: EXPERIMENTAL
Intervention: High eye contact (85%)
Number of subjects: 48
Study 662565 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium eye contact (50%)
Number of subjects: 48
Study 662565 — intervention group
Group type: COMPARATOR
Intervention: Low eye contact (15%)
Number of subjects: 48
Study 662565 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-to-eye direction
Number of subjects: 48
Study 662565 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-to-nose/mouth direction
Number of subjects: 48